全文获取类型
收费全文 | 7607篇 |
免费 | 576篇 |
国内免费 | 318篇 |
专业分类
耳鼻咽喉 | 45篇 |
儿科学 | 86篇 |
妇产科学 | 29篇 |
基础医学 | 842篇 |
口腔科学 | 151篇 |
临床医学 | 514篇 |
内科学 | 694篇 |
皮肤病学 | 571篇 |
神经病学 | 1697篇 |
特种医学 | 222篇 |
外科学 | 429篇 |
综合类 | 807篇 |
现状与发展 | 2篇 |
预防医学 | 352篇 |
眼科学 | 245篇 |
药学 | 1233篇 |
1篇 | |
中国医学 | 365篇 |
肿瘤学 | 216篇 |
出版年
2024年 | 9篇 |
2023年 | 154篇 |
2022年 | 199篇 |
2021年 | 344篇 |
2020年 | 306篇 |
2019年 | 266篇 |
2018年 | 253篇 |
2017年 | 243篇 |
2016年 | 278篇 |
2015年 | 274篇 |
2014年 | 421篇 |
2013年 | 508篇 |
2012年 | 421篇 |
2011年 | 455篇 |
2010年 | 384篇 |
2009年 | 356篇 |
2008年 | 363篇 |
2007年 | 338篇 |
2006年 | 331篇 |
2005年 | 258篇 |
2004年 | 192篇 |
2003年 | 194篇 |
2002年 | 165篇 |
2001年 | 162篇 |
2000年 | 141篇 |
1999年 | 120篇 |
1998年 | 110篇 |
1997年 | 103篇 |
1996年 | 90篇 |
1995年 | 78篇 |
1994年 | 81篇 |
1993年 | 69篇 |
1992年 | 71篇 |
1991年 | 69篇 |
1990年 | 40篇 |
1989年 | 64篇 |
1988年 | 54篇 |
1987年 | 55篇 |
1986年 | 66篇 |
1985年 | 61篇 |
1984年 | 72篇 |
1983年 | 42篇 |
1982年 | 53篇 |
1981年 | 46篇 |
1980年 | 47篇 |
1979年 | 31篇 |
1978年 | 24篇 |
1977年 | 11篇 |
1976年 | 12篇 |
1975年 | 6篇 |
排序方式: 共有8501条查询结果,搜索用时 31 毫秒
21.
22.
《Journal of pharmaceutical sciences》2019,108(10):3425-3433
This study aimed at evaluating how encapsulation in a regular nanocarrier (NC) (providing extended circulation time) or in a brain-targeting NC (providing prolonged circulation time and increased brain uptake) may influence the therapeutic index compared with the unformulated drug and to explore the key parameters affecting therapeutic performance using a model-based approach. Pharmacokinetic (PK) models were built with chosen PK parameters. For a scenario where central effect depends on area under the unbound brain concentration curve and peripheral toxicity relates to peak unbound plasma concentration, dose-effect and drug-side effect curves were constructed, and the therapeutic index was evaluated. Regular NC improved the therapeutic index compared with the unformulated drug due to reduced peripheral toxicity, while brain-targeting NC enhanced the therapeutic index by lowering peripheral toxicity and increasing central effect. Decreasing drug release rate or systemic clearance of NC with drug still encapsulated could increase the therapeutic index. Also, a drug with shorter half-life would therapeutically benefit more from a NC encapsulation. This work provides insights into how a NC for brain delivery should be optimized to maximize the therapeutic performance and is helpful to predict if and to what extent a drug with certain PK properties would obtain therapeutic benefit from nanoencapsulation. 相似文献
23.
24.
Glucose is the primary energy source for the brain, and exposure to both high and low levels of glucose has been associated with numerous adverse central nervous system (CNS) outcomes. While a large body of work has highlighted the impact of hyperglycemia on peripheral and central measures of oxidative stress, cognitive deficits, and vascular complications in Type 1 and Type 2 diabetes, there is growing evidence that glycemic variability significantly drives increased oxidative stress, leading to neuroinflammation and cognitive dysfunction. In this review, the latest data on the impact of glycemic variability on brain function and neuroinflammation will be presented. Because high levels of oxidative stress have been linked to dysfunction of the blood–brain barrier (BBB), special emphasis will be placed on studies investigating the impact of glycemic variability on endothelial and vascular inflammation. The latest clinical and preclinical/in vitro data will be reviewed, and clinical/therapeutic implications will be discussed. 相似文献
25.
Christopher D Hue Frances S Cho Siqi Cao Cameron R ”Dale” Bass David F Meaney Barclay Morrison III 《Journal of cerebral blood flow and metabolism》2015,35(7):1191-1198
Owing to the frequent incidence of blast-induced traumatic brain injury (bTBI) in recent military conflicts, there is an urgent need to develop effective therapies for bTBI-related pathologies. Blood-brain barrier (BBB) breakdown has been reported to occur after primary blast exposure, making restoration of BBB function and integrity a promising therapeutic target. We tested the hypothesis that treatment with dexamethasone (DEX) after primary blast injury potentiates recovery of an in vitro BBB model consisting of mouse brain endothelial cells (bEnd.3). DEX treatment resulted in complete recovery of transendothelial electrical resistance and hydraulic conductivity 1 day after injury, compared with 3 days for vehicle-treated injured cultures. Administration of RU486 (mifepristone) inhibited effects of DEX, confirming that barrier restoration was mediated by glucocorticoid receptor signaling. Potentiated recovery with DEX treatment was accompanied by stronger zonula occludens (ZO)-1 tight junction immunostaining and expression, suggesting that increased ZO-1 expression was a structural correlate to BBB recovery after blast. Interestingly, augmented ZO-1 protein expression was associated with specific upregulation of the α+ isoform but not the α− isoform. This is the first study to provide a mechanistic basis for potentiated functional recovery of an in vitro BBB model because of glucocorticoid treatment after primary blast injury. 相似文献
26.
27.
目的观察胆道结石合并糖尿病患者腹腔镜胆囊切除术(LC)后肠屏障功能的变化。方法将择期行LC的126例患者分为糖尿病组41例和非糖尿病组85例。术前及术后第1、3天,采用高效液相色谱法检测尿乳果糖与甘露醇比值(L/M),并采用酶联免疫吸附法(ELISA)检测尿脂肪酸结合蛋白(IFABP)及血清D-乳酸水平。结果2组患者均成功完成手术,无中转开放手术者。糖尿病组术后肛门排气时间长于非糖尿病组,差异有统计学意义(P<0.05)。糖尿病组术后第1、3天尿L/M、血清D-乳酸、尿IFABP均高于术前及非糖尿病组,差异均有统计学意义(P<0.05)。结论合并糖尿病的胆道结石患者行LC后会加重肠屏障功能障碍程度,术前控制好血糖水平或可降低肠道功能损伤的严重程度。 相似文献
28.
目的:探讨健脾解毒凉血方治疗肝损伤肠屏障功能障碍的作用靶点。方法:选取C57BL/6雄性小鼠32只,随机分为正常组、模型组、中药组、培菲康组,腹腔注射硫代乙酰胺100 mg/kg造模;中药组予以健脾解毒凉血方灌胃,培菲康组给予培菲康溶液灌胃;16 h后采集小鼠血清、肝组织、小肠组织,观察小鼠肝功能、肠道组织HE染色变化,免疫组织化学染色方法观察小肠闭锁小带蛋白-1表达。结果:模型组、中药组、培菲康组小鼠的ALT、AST均显著高于正常组,模型组、中药组、培菲康组比较差异无统计学意义(P0.05)。小肠组织在光镜和电镜下均可观察到中药组病变轻于模型组和培菲康组,免疫组织化学染色在小肠上皮细胞上可见闭锁小带蛋白-1棕黄色阳性标记,模型组、中药组、培菲康组阳性标记均显著少于正常组,中药组阳性标记显著多于模型组(P0.05)。结论:健脾解毒凉血方治疗硫代乙酰胺诱导急性肝损伤小鼠,可维护肠上皮细胞紧密连接部闭锁小带蛋白-1表达,修复肠屏障功能。 相似文献
29.
30.
《药学学报(英文版)》2020,10(4):646-666
Drug repurposing is an efficient strategy for new drug discovery. Our latest study found that nitazoxanide (NTZ), an approved anti-parasite drug, was an autophagy activator and could alleviate the symptom of Alzheimer's disease (AD). In order to further improve the efficacy and discover new chemical entities, a series of NTZ-based derivatives were designed, synthesized, and evaluated as autophagy activator against AD. All compounds were screened by the inhibition of phosphorylation of p70S6K, which was the direct substrate of mammalian target of rapamycin (mTOR) and its phosphorylation level could reflect the mTOR-dependent autophagy level. Among these analogs, compound 22 exhibited excellent potency in promoting β-amyloid (Aβ) clearance, inhibiting tau phosphorylation, as well as stimulating autophagy both in vitro and in vivo. What's more, 22 could effectively improve the memory and cognitive impairments in APP/PS1 transgenic AD model mice. These results demonstrated that 22 was a potential candidate for the treatment of AD. 相似文献